MedTrace Logo

A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer

NCT06614621 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2024-09-26

No results posted yet for this study

Summary

A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer

Conditions

  • Extensive-Stage Small Cell Lung Cancer

Interventions

DRUG

Adebrelimab +Etoposide+Platinum-based drugs

Adebrelimab：20mg/kg或1200mg ivgtt ，d1 ，Q3W Etoposide injection (E): 100mg/m2, ivgtt, d1,d2,d3,Q3W Platinum-based drugs：75mg/m2， ivgtt， d1,d2,d3,Q3W

DRUG

Maintenance treatment period:

Adebrelimab：20mg/kg或1200mg，IV, Q3W； Apatinib Mesylate Tablets：250mg，P.O，qod

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2027-12-01
Completion
2028-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06614621 on ClinicalTrials.gov